CN102258540A - Application of probiotic factor and lactobacillus mixture to preventing and treating vaginitis - Google Patents
Application of probiotic factor and lactobacillus mixture to preventing and treating vaginitis Download PDFInfo
- Publication number
- CN102258540A CN102258540A CN2010101836506A CN201010183650A CN102258540A CN 102258540 A CN102258540 A CN 102258540A CN 2010101836506 A CN2010101836506 A CN 2010101836506A CN 201010183650 A CN201010183650 A CN 201010183650A CN 102258540 A CN102258540 A CN 102258540A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- factor
- vaginitis
- mixture
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of a probiotic factor and lactobacillus mixture to preventing and treating vaginitis. The probiotic factor can be used for promoting propagation of beneficial bacteria, lactobacillus and bifidobacterium, in a woman vagina and suppressing growth of pathogenic bacteria of the vagina through site competition and hydrogen peroxide secretion. Meanwhile, a weakly acidic environment of the vagina can be maintained and the pH value of the vagina can be adjusted through the propagation of the lactobacillus. The vaginal probiotic bacteria can be effectively supplemented, quick propagation of the probiotic bacteria can be facilitated and a dominant position of a vaginal flora structure can be occupied through the addition of the lactobacillus. By effectively combining the probiotic factor and the lactobacillus, the mixture has an obvious effect of preventing and treating the vaginitis, particularly recurrent vaginitis.
Description
Technical field
The present invention relates to probiotics factor and lactobacillus, particularly probiotics factor and the lactobacillus mixture application aspect prevention and treatment vaginitis.
Background technology
Vaginitis be the women in life all in the common disease of facing, treat vaginitis at present and mainly rely on antibiotic and chemical synthetic drug, when killing pathogenic bacterium, also kill probiotics, cure back vaginal microbial flora fragile structure, vaginitis recurs easily.Need a kind of more effective method of killing pathogenic bacterium.Simultaneously, the frequent use of antibiotic and chemical synthetic drug causes drug-fast generation, causes vaginitis treatment to be wasted time and energy, poor effect.
At present international and domestic have portioned product to use microecology knowledge, treats vaginitis with lactobacillus preparation, obtains certain curative effect.But lactobacillus preparation is an active bacteria formulation, and the shelf-life is short, and vigor descends fast.Promote not good in actual applications.Single lactobacillus preparation needs and other antibacterial competitions after entering vagina, and some patient's internal milieu is not suitable for lactobacillus growth, causes the treatment failure.Can promote lactobacillus to breed fast by adding the probiotics factor that is fit to the breeding of lactobacillus specificity, occupy the main status of vaginal microbial flora structure rapidly, efficiently solve these problems.
Be applied to aspect the vaginitis treatment at probiotics factor, report lessly so far, only have Yang Suzhen etc. to apply for that 20081009191.2 oligomeric xylose is in the application aspect treatment and the prevention vaginitis.But a kind of probiotics factor of single use is because excessive concentration causes antibacterial to produce adaptability easily.And can not be fit to the different demands of probiotic bacteria in the groups of people colony.Combination with several probiotics factor can effectively address this problem.Simultaneously, single utilization probiotics factor may meet with part patient intravaginal does not have probiotic bacteria or probiotic bacteria number situation very little, causes the treatment failure.Therefore need to add lactobacillus and solve this problem.
Summary of the invention
The technical problem to be solved in the present invention is the deficiency that overcomes the said goods, and probiotics factor and lactobacillus mixture application and the dosage form thereof aspect prevention and treatment vaginitis is provided.Be applicable to and safeguard normal flora structure in the daily life, promote vagina probiotic bacteria propagation, prevent and resist the gynaecopathia invasion and attack.Be applicable to independent treatment vaginitis or auxiliary treatment vaginitis, be applicable to colpitic recurrence simultaneously.
To achieve these goals, the technological means taked of the present invention is a kind of probiotics factor and lactobacillus mixture.Probiotics factor is a polysaccharide, oligosaccharide or its complex.Lactobacillus is the lactobacillus of isolating product hydrogen peroxide in normal women's body.Concrete composition proportion is: in per 100 gram products, and lactobacillus 20-40 gram, probiotics factor 30-50 gram, pharmaceutic adjuvant 10-50 gram.
The polysaccharide of indication of the present invention is a chitosan.Chitosan, English name Chitosan.Molecular formula: (C
6H
11NO
4) n, be the product of chitin behind deacetylation.Chitosan has obvious suppression mycete, antibacterial and zymic effect.Chitosan is used for product, can effectively suppress and kill harmful microorganisms such as mycete, antibacterial, thereby eliminates because microorganism encroach and inflammation, can eliminate simultaneously owing to melanin that microbial accumulation causes, mottle etc.Chitosan itself can also suppress the activity that melanin forms enzyme, thereby eliminates the melanin that causes owing to Metabolic disorder.
The amino that many bound water molecules are arranged on the chitosan macromole has good water absorption and water-retaining property.Human body skin can produce dry and cracked owing to reasons such as Exposure to Sunlight, drying and agings; Along with the increase at age, the reproduction speed of human body cell slows down, and it is the wrinkle that we often say that the epidermis cell gathering can produce the space, chitosan can be filled in the dry and cracked seam of skin generation, with ceramide effect in the epidermal lipid rete, the final sum epidermis grows up to one, to reach the effect of repairing epidermis.In addition, chitosan still is a kind of good cell growth inducing factor, has been widely used in the enrichment culture of animal and plant cells at present.When being used for product, it can stimulate the reproduction speed of accelerating epidermis cell, thereby reaches the delaying senility effect.
Oligosaccharide of the present invention comprises oligofructose, oligomeric xylose, oligochitosan, stachyose, oligomeric galactose.(Fructooligosaccharide FOS) is the mixture that is combined ketose, C24H42 O21 and the Fructofuranosyl nystose etc. that generate by 1～3 fructosyl by β (2-1) glycosidic bond and the fructosyl in the sucrose to oligofructose.
Oligofructose is a kind of natural active matter.Have the adjusting intestinal microbial population, the propagation bacillus bifidus promotes the absorption of calcium, blood lipid regulation, health cares such as immunomodulating.In numerous food such as milk product, lactobacillus beverage, solid beverage, confection, cookies, bread, fruit jelly, cold drink, use.
Oligofructose is except that the physicochemical properties with general utility functions oligosaccharide, the most noticeable physiological property is that it can obviously improve microbial population ratio in the intestinal, it is the activation and proliferation factor of enteral bacillus bifidus, can reduce and suppress the generation of enteral corrupt substance, suppress the growth of noxious bacteria, regulate the intestinal inner equilibrium; Can promote the absorption and the utilization of trace elements iron, calcium, to prevent osteoporosis; Can reduce hepatotoxin, can in intestinal, generate anticancer organic acid, significant preventing cancer function is arranged.Oligosaccharide of the present invention comprises oligomeric xylose.Oligomeric xylose is by the functional polymerization sugar of 2-7 xylose molecule with β-1,4 glycosidic bond be combined into.It can optionally promote the proliferation activity of intestinal bifidobacteria.Its bifidobacterium factor functional is 10-20 a times of other polymerization saccharide.
Oligomeric xylose is one of the strongest kind of polymerization sugar apoplexy due to endogenous wind propagation bacillus bifidus function, its effect is nearly 20 times of other polymerization saccharides, the enzyme that does not have the hydrolysis oligomeric xylose in the human gastrointestinal tract, so it can directly enter big enteral and be preferably bacillus bifidus and utilize, promote bacillus bifidus propagation to produce multiple organic acid simultaneously.Reduce the intestinal pH value, suppress harmful bacteria growing, probiotic bacteria is bred in a large number at intestinal.
Oligosaccharide of the present invention comprises oligochitosan.Oligochitosan (Chitosan oligosaccharide) also claims chitin oligosaccharide, and formal name used at school is β-1, and 4-oligomerization glucamine is the low molecular weight product that good water solubility, function are big, biological activity is high that chitosan forms through the biotechnology degraded.Oligochitosan is nearly 100% in the human body internal absorption factor, and its effect is tens of times of chitosan.Oligochitosan has the immunity of raising, suppresses the growth of cancerous protuberance cell, promotes liver spleen antibody to form, and promotes the absorption of calcium and mineral, functions such as human body beneficial's flora such as propagation bacillus bifidus, lactobacillus.Can be applicable to fields such as medicine, functional food.Oligochitosan can obviously be eliminated the human body oxygen-derived free radicals, the activation equipment somatic cell, and slow down aging suppresses the harmful bacterium of skin surface and grows the performance of keeping humidity excellence.Oligochitosan not only possesses water solublity, and is easy to use, and it is remarkable to suppress the putrefaction bacteria impact of performance, has both multiple function, is the natural additive of function admirable.
Oligosaccharide of the present invention comprises oligomeric galactose.The main sugared composition of oligomeric galactose (GOS) is a galactose, and the gala pyrans glycosyl units that is connected by several β-(1 → 6) key on the structure links to each other with a Glucopyranyl unit by α-(1 → 4) glucoside bond.Oligomeric galactose is the oligosaccharide that exists in the breast milk, is characterized in Heat stability is good, under neutral, acid condition, be heated to 120 ℃ non-degradable.Different with oligofructose, it has the effect of propagation simultaneously to the bacillus bifidus of enteral and lactobacillus, and can suppress harmful bacterium and grow.Heat is 50% of a general saccharide, has the effectiveness identical with dietary fiber, can promote enterogastric peristalsis, improves function of intestinal canal.
Oligosaccharide of the present invention comprises stachyose.Stachyose is a kind of naturally occurring tetrose, and molecular formula is C
24H
42O
21, be a kind of functional oligose that can significantly promote bacillus bifidus propagation.Stachyose is similar to some water soluble dietary fiber, and is nontoxic, direct-edible; Profitable strains such as the bacillus bifidus in the human gastrointestinal tract, lactobacillus there is extremely significantly proliferation function, can improves environment in the human body alimentary canal rapidly; In organs such as the stomach of human body, small intestinal, be not destroyed, can directly arrive the large intestine position at intestinal beneficial bacterium group place, significantly promote bacillus bifidus propagation; Stachyose can promote the synthetic of vitamin such as B1, B2, B6, B12, promotes the absorption of gastrointestinal tract to elements such as calcium, magnesium; Do not produce abdominal distention after taking; Active factors is arranged, adsorbable gastrointestinal tract noxious substance and pathogen, and then strengthen body immunity.Stachyose is adopted by medicine and healthcare industry gradually and is widely used.
Lactobacillus of the present invention is the lactobacillus of isolating product hydrogen peroxide in normal women's body.During lactobacillus had a lot, the human body different parts separated the lactobacillus that obtains, and its field planting ability is different.The strong bacterial strain that separation obtains in the healthy women body helps the field planting at vagina.Intravaginal is simultaneously played the lactobacillus of main defense function for producing the lactobacillus of hydrogen peroxide.Lactobacillus can be colonizated in vagina and growth and breeding, and its metabolite lactic acid and hydrogen peroxide can keep the normal sour environment of vagina on the one hand, on the other hand, can suppress or kill other antibacterials and comprise anaerobe.Lactobacillus is normal intravaginal dominant bacteria, and it can be a lactic acid with glycogenolysis, keeps the normal sour environment of vagina, and the pathogen that adapts to existence under the weakly alkaline environment is suppressed.
Also contain the pharmaceutic adjuvant composition in the product of the present invention, as the paraffin of oleaginous base class, vaseline, oils and fats etc.; The carbomer of aqueous matrix class, polyvinylpyrrolidone, cellulose etc.; PH regulator agent such as citric acid, lactic acid, sodium hydroxide etc.; Surfactant A EO, sodium lauryl sulphate etc.; Disintegrating agent such as dried starch, cross-linked carboxymethyl cellulose etc.; Antiseptic such as hibitane, parabens etc. and other all pharmaceutic adjuvants.
Dosage form of the present invention is a suppository for its form, effervescent tablet, gel, powder, spray, washing liquid, unguentum or other dosage forms.
The specific embodiment
Component and the weight proportion thereof of the specific embodiment 1-8 of this programme see the following form:
Embodiment 123456
Lactobacillus 30 30 30 40 40 40
Chitosan 10 10-10 0-
Oligofructose 10 10----
Oligomeric xylose 10 10 10 20-15
Oligomeric galactose 10-10-10 10
Stachyose 10 10---10
Oligochitosan 10 10 10 20 20 10
Pharmaceutic adjuvant 10 20 40 10 30 15
The concrete preparation method of above-mentioned embodiment of the present invention is:
Get an amount of sterilized water, all sugar that need add are dissolved in the sterilized water successively, use the membrane filtration degerming, obtain the sugar juice of degerming.Vacuum freeze-drying.Add lactobacillus, stir.Add the prefabricated pharmaceutic adjuvant of getting ready, be prepared into the appropriate formulation form.
The above only is a preferable embodiment of the present invention, and any modification, equivalent variations and the modification that every foundation technical spirit of the present invention is made above embodiment all belongs to the scope of technical solution of the present invention.
Claims (7)
1. probiotics factor and the lactobacillus mixture application aspect prevention and treatment vaginitis.
2. as right 1 described application, its feature exists: contain lactobacillus and probiotics factor in the product, in 100 gram products, the ratio of lactobacillus is the 10-40 gram, and the probiotics factor ratio is the 30-50 gram, and the pharmaceutic adjuvant ratio is the 10-60 gram.
3. as right 1 described application, its probiotics factor is polysaccharide or oligosaccharide or its mixture.
4. as right 1 described application, its polysaccharide is a chitosan.
5. as right 1 described application, its oligosaccharide class is the one or more kinds of mixture in oligochitosan, oligofructose, oligomeric xylose, stachyose and the oligomeric galactose.
6. as right 1 described application, its lactobacillus is the lactobacillus of isolating product hydrogen peroxide in the healthy women vagina.
7. as right 1 described application, its form is a suppository, effervescent tablet, gel, powder, spray, washing liquid, unguentum or other dosage forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101836506A CN102258540A (en) | 2010-05-25 | 2010-05-25 | Application of probiotic factor and lactobacillus mixture to preventing and treating vaginitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101836506A CN102258540A (en) | 2010-05-25 | 2010-05-25 | Application of probiotic factor and lactobacillus mixture to preventing and treating vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102258540A true CN102258540A (en) | 2011-11-30 |
Family
ID=45005506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101836506A Pending CN102258540A (en) | 2010-05-25 | 2010-05-25 | Application of probiotic factor and lactobacillus mixture to preventing and treating vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102258540A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626424A (en) * | 2012-04-28 | 2012-08-08 | 王飞 | Active bacteriostasis capsule |
| CN103110973A (en) * | 2013-01-24 | 2013-05-22 | 量子高科(中国)生物股份有限公司 | Method for protecting reproductive tract microecological health balance |
| CN106166163A (en) * | 2016-09-05 | 2016-11-30 | 北京蓝色美城科技有限公司 | A kind of feminine wash of the fermentation supernatant containing lactic acid bacteria |
| CN108066278A (en) * | 2017-12-21 | 2018-05-25 | 广州润虹医药科技股份有限公司 | A kind of gynaecology's gel containing chitosan oligosaccharide and preparation method thereof |
| CN108096327A (en) * | 2017-12-29 | 2018-06-01 | 广州润虹医药科技股份有限公司 | A kind of Gynaecological suppository containing chitosan oligosaccharide and preparation method thereof |
| CN109106806A (en) * | 2018-06-20 | 2019-01-01 | 广州宏韵医药科技股份有限公司 | A kind of women secret nursing washing lotion and preparation method thereof |
| CN109674828A (en) * | 2019-02-18 | 2019-04-26 | 深圳汉朔建元健康管理有限公司 | A kind of preparation and preparation method thereof for rebuilding vaginal flora balance |
| CN110327287A (en) * | 2019-08-05 | 2019-10-15 | 江西鼎中科技有限公司 | It is a kind of for prevent and treat vaginitis containing lactose prod and its production technology |
| CN111632073A (en) * | 2019-03-01 | 2020-09-08 | 王飞 | Antibacterial and anti-inflammatory female privates probiotic composition and preparation thereof |
| CN112386625A (en) * | 2019-08-13 | 2021-02-23 | 辽宁瑞美药业有限公司 | Gel composition for treating gynecological inflammation and preparation method thereof |
-
2010
- 2010-05-25 CN CN2010101836506A patent/CN102258540A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626424A (en) * | 2012-04-28 | 2012-08-08 | 王飞 | Active bacteriostasis capsule |
| CN103110973A (en) * | 2013-01-24 | 2013-05-22 | 量子高科(中国)生物股份有限公司 | Method for protecting reproductive tract microecological health balance |
| CN106166163A (en) * | 2016-09-05 | 2016-11-30 | 北京蓝色美城科技有限公司 | A kind of feminine wash of the fermentation supernatant containing lactic acid bacteria |
| CN108066278A (en) * | 2017-12-21 | 2018-05-25 | 广州润虹医药科技股份有限公司 | A kind of gynaecology's gel containing chitosan oligosaccharide and preparation method thereof |
| CN108096327A (en) * | 2017-12-29 | 2018-06-01 | 广州润虹医药科技股份有限公司 | A kind of Gynaecological suppository containing chitosan oligosaccharide and preparation method thereof |
| CN109106806A (en) * | 2018-06-20 | 2019-01-01 | 广州宏韵医药科技股份有限公司 | A kind of women secret nursing washing lotion and preparation method thereof |
| CN109674828A (en) * | 2019-02-18 | 2019-04-26 | 深圳汉朔建元健康管理有限公司 | A kind of preparation and preparation method thereof for rebuilding vaginal flora balance |
| CN111632073A (en) * | 2019-03-01 | 2020-09-08 | 王飞 | Antibacterial and anti-inflammatory female privates probiotic composition and preparation thereof |
| CN110327287A (en) * | 2019-08-05 | 2019-10-15 | 江西鼎中科技有限公司 | It is a kind of for prevent and treat vaginitis containing lactose prod and its production technology |
| CN112386625A (en) * | 2019-08-13 | 2021-02-23 | 辽宁瑞美药业有限公司 | Gel composition for treating gynecological inflammation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258540A (en) | Application of probiotic factor and lactobacillus mixture to preventing and treating vaginitis | |
| Zheng et al. | Current trends in marine algae polysaccharides: The digestive tract, microbial catabolism, and prebiotic potential | |
| CN104758318B (en) | A kind of compound formulation and preparation method thereof reducing diarrhea of weaned piglets rate | |
| Qiang et al. | Health benefit application of functional oligosaccharides | |
| ES2180321T5 (en) | Carbohydrate blends | |
| CN1663573B (en) | A stable and safe microecological formulation, its preparation and usage | |
| ES2284028T5 (en) | New composition of galactooligosaccharide and its preparation | |
| CN104983746B (en) | Complex probiotics and preparation method thereof | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN104642870B (en) | A kind of prebiotic compositions | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| JPH11504049A (en) | Compositions for genitourinary and intestinal disorders, comprising substances from plant species of the azalea family and lactic acid bacterial growth factor | |
| CN110141585A (en) | A kind of composite probiotics ferment microbial inoculum and preparation method thereof for adjusting intestinal flora | |
| CN102670662A (en) | Uronic acid and probiotics | |
| CN102258532A (en) | Application of probiotic factor compound in preventing and treating colpitis | |
| CN111227261A (en) | Prebiotic composition and application thereof | |
| CN111771971A (en) | Composition beneficial to regulating intestinal tract, promoting digestion and improving constipation and preparation method thereof | |
| CN109475151A (en) | Control the immunological regulation of harmful bacteria and growth promotion composition and application thereof in intestinal microbiota | |
| CN106509440A (en) | Health-care feed additive for multiparous sows | |
| CN109718289A (en) | A kind of galactooligosaccharide prebiotic compositions treating or preventing enterogastric diseases | |
| CN105982009A (en) | Composition for regulating human body intestinal micro-ecology | |
| CN102811720A (en) | Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells | |
| CN107889997A (en) | A kind of Freeze-dry Powder of Probioctics solid beverage | |
| CN107927788A (en) | A kind of oligosaccharide nutrient | |
| CN104161874A (en) | Compound traditional Chinese medicine composition for preventing and treating piglet bacillary dysentery and its preparation method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| DD01 | Delivery of document by public notice |
Addressee: Shanghai Duyite Medical Device Co.,Ltd. Xing Jianhui Document name: Notification of Publication of the Application for Invention |
|
| DD01 | Delivery of document by public notice |
Addressee: Shanghai Duyite Medical Device Co.,Ltd. Document name: Notification of before Expiration of Request of Examination as to Substance |
|
| DD01 | Delivery of document by public notice |
Addressee: Shanghai Duyite Medical Device Co.,Ltd. Document name: Notification that Application Deemed to be Withdrawn |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111130 |